Washington-area businesses raised more venture capital in the fourth quarter than they had in any quarter since 2001 — largely due to a few large deals.
The surge is not likely to be repeated soon given the recent stock market turmoil. Indeed, venture funding nationally declined during the period.
The TCM Industry Awards Celebration is the only awards ceremony that honors the best in Maryland’s technology and life science communities and is one of Maryland’s largest and most prestigious award ceremonies.
Awards go to those who develop the treatments, design the systems, and teach the children. It’s a celebration of great minds and the companies that believe in the future, and is attended by over 800 executives from the technology and life science industries, drawing a significant amount of local and national publicity.
What’s the difference between a relatively flat economy and a vibrant and diversified region with high job and economic growth? Working together. That was the pitch Thursday morning as economist Steve Fuller unveiled the findings after months of research for a project dubbed “ The Roadmap for the Washington Region’s Economic Future.”
You’ve heard of 3-D printers creating architectural models, airplane parts and even prosthetic limbs. But bones? Warren Grayson, an assistant professor of biomedical engineering at Johns Hopkins University, says it’s possible and not so far off in the future.
TPG Growth, the middle market and growth equity investment platform of TPG, a leading global private investment firm with approximately $70 billion of assets under management, today announced a $75 million investment in Precision for Medicine, Inc. Additional details of the transaction were not disclosed.
Kenneth Clark remembers the last time new investors moved into biotech. They came in the late 1980s.
They left in the early ’90s.
GE Healthcare, the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), and the Centre for Commercialization of Regenerative Medicine (CCRM) are building a centre for advanced therapeutic cell technologies in Toronto with an investment of CAD $40M from GE and FedDev Ontario. The centre is being established to accelerate the development and adoption of cell manufacturing technologies that improve patient access to novel regenerative medicine-based therapies. CCRM and GE will welcome partners from pharma, biotech and cell therapy companies to bring this initiative to life.
It wasn’t expected to be a major State of the Union address—a final speech from a president in his last term, recounting achievements and expressing hope for the future. And then Obama made some news: “Let’s make America the country that cures cancer once and for all.” And to lead the administration’s effort, the president picked VP Joe Biden, who recently lost his son Beau to cancer, and who has said that finding a cure is one of his major life goals
ATCC, the premier global biological materials resource and standards organization, announces today that it licensed CRISPR/Cas9 gene editing technology from the Broad Institute of MIT and Harvard. ATCC plans to use the gene editing technology to develop a portfolio of new products and services to support basic and translational research.
Ligand Pharmaceuticals enters into a global license agreement with Emergent BioSolutions under which Emergent will use Ligand’s OmniRat, OmniMouse and OmniFlic technologies to discover fully human mono- and bispecific antibodies.
